SELLAS Life Sciences Group Inc is a biotechnology business based in the US. SELLAS Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. SELLAS Life Sciences Group employs 7 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.73 |
|---|---|
| 52-week range | $4.25 - $15.08 |
| 50-day moving average | $6.23 |
| 200-day moving average | $8.62 |
| Wall St. target price | $17.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.73 from 2022-01-27
| 1 week (2022-01-17) | N/A |
|---|---|
| 1 month (2021-12-24) | N/A |
| 3 months (2021-10-28) | -45.51% |
| 6 months (2021-07-28) | -46.31% |
| 1 year (2021-01-28) | -14.00% |
|---|---|
| 2 years (2020-01-28) | 63.67% |
| 3 years (2019-01-28) | 219.59% |
| 5 years (2017-01-27) | 171.84% |
| Revenue TTM | $9.5 million |
|---|---|
| Gross profit TTM | $1.9 million |
| Return on assets TTM | -39.48% |
| Return on equity TTM | -103.12% |
| Profit margin | -187.55% |
| Book value | $1.68 |
| Market capitalisation | $80.5 million |
TTM: trailing 12 months
We're not expecting SELLAS Life Sciences Group to pay a dividend over the next 12 months.
SELLAS Life Sciences Group's shares were split on a 1:50 basis on 7 November 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your SELLAS Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for SELLAS Life Sciences Group shares which in turn could have impacted SELLAS Life Sciences Group's share price.
Over the last 12 months, SELLAS Life Sciences Group's shares have ranged in value from as little as $4.25 up to $15.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SELLAS Life Sciences Group's is 1.6132. This would suggest that SELLAS Life Sciences Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co. , Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.